SCHAUMBURG, Ill., Nov 1 (Bernama-GLOBE NEWSWIRE) -- International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a global company that provides laboratory and consultative services to the biopharmaceutical industry involved in the development of products for the prevention, control and treatment of infectious diseases has announced the establishment of an affiliate in India (IHMA India, LLP). The affiliate will greatly facilitates IHMA’s ability to provide global services to the anti-infective industry.
There is an urgent need for new effective anti-infectives. India is a very important market and a major focus for pharmaceutical companies with anti-infectives in late-phase development. Although IHMA has worked in collaboration with pharmaceutical companies and academic laboratories in India for many years, IHMA India LLP will allow IHMA to further establish itself in India allowing for even better co-ordination and management of such studies to benefit the medical community.
"I am very pleased to be involved with the setting up of this new IHMA company, and I look forward to establishing IHMA’s suite of molecular and conventional clinical microbiology services in India," said Dr. Tarun Mathur, CEO of IHMA India LLP.
"IHMA is very excited about our expansion into India. This new company gives us the ability and bandwidth to better support the biopharmaceutical industry’s surveillance and clinical trial needs in this region," said Dr. Ian Morrissey, Chief Scientific & Development Officer at IHMA Europe Sàrl.
“We have been working very hard over the past 26 years to maximize our in vitro support for clients who are developing antimicrobials in a global market. Our facility in India will greatly enhance that effort and support clients wishing to conduct studies in this important market,” said Jack L. Johnson, President/CEO of IHMA.
There is an urgent need for new effective anti-infectives. India is a very important market and a major focus for pharmaceutical companies with anti-infectives in late-phase development. Although IHMA has worked in collaboration with pharmaceutical companies and academic laboratories in India for many years, IHMA India LLP will allow IHMA to further establish itself in India allowing for even better co-ordination and management of such studies to benefit the medical community.
"I am very pleased to be involved with the setting up of this new IHMA company, and I look forward to establishing IHMA’s suite of molecular and conventional clinical microbiology services in India," said Dr. Tarun Mathur, CEO of IHMA India LLP.
"IHMA is very excited about our expansion into India. This new company gives us the ability and bandwidth to better support the biopharmaceutical industry’s surveillance and clinical trial needs in this region," said Dr. Ian Morrissey, Chief Scientific & Development Officer at IHMA Europe Sàrl.
“We have been working very hard over the past 26 years to maximize our in vitro support for clients who are developing antimicrobials in a global market. Our facility in India will greatly enhance that effort and support clients wishing to conduct studies in this important market,” said Jack L. Johnson, President/CEO of IHMA.
No comments:
Post a Comment